Compare Amgen, Inc. (AMGN) vs DoorDash Inc (DASH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs DoorDash Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while DoorDash Inc trades at $192 (market cap $83.58B). The key difference: Amgen, Inc. is far larger — about 2.3× DoorDash Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.
| AMGN | DASH | |
|---|---|---|
Market Cap | $196.12B | $83.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $281.74 |
52-Week Low | $271.18 | $146.60 |
Enterprise Value | $241.41B | $81.33B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DoorDash (DASH) trades at $191.82, down 0.28% on the day, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $13.72 billion in 2025, and has turned profitable with a net income margin of 6.29%. Recent news highlights expansion into grocery delivery and AI integration, while technical indicators suggest key resistance near $200.
The outlook remains positive due to market dominance and international expansion, but risks include intense competition and valuation concerns with a P/E of 90.91. Analysts project a consensus price target of $231.50, implying significant upside, though upcoming Q2 2026 earnings on August 5 will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
